Linxiang Lan

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma.

NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma.

Journal: Cancer immunology, immunotherapy : CII
Published: December 11, 2025

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway.

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway.

Journal: Frontiers in cell and developmental biology
Published: July 24, 2025

Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription.

Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription.

Journal: EBioMedicine
Published: July 07, 2025

A Jagged1-regulated hybrid-EMT state identifies pancreatic cancer stem cells.

A Jagged1-regulated hybrid-EMT state identifies pancreatic cancer stem cells.

Journal: Cell reports
Published: March 04, 2025

SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer.

SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer.

Journal: Nature
Published: November 25, 2024

Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance.

Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance.

Journal: Developmental cell
Published: October 12, 2024

NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance.

NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance.

Journal: Nature
Published: April 18, 2023

Are There Specific Cancer Stem Cell Markers?

Are There Specific Cancer Stem Cell Markers?

Journal: Cancer research
Published: August 17, 2022

METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.

METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.

Journal: Cellular and molecular life sciences : CMLS
Published: September 27, 2021

USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.

USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.

Journal: eLife
Published: June 24, 2021

PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.

PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.

Journal: Frontiers in cell and developmental biology
Published: June 02, 2021

GREM1 is required to maintain cellular heterogeneity in pancreatic cancer.

GREM1 is required to maintain cellular heterogeneity in pancreatic cancer.

Journal: Nature
Published: September 01, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026